-
Mycobacterium tuberculosis transmission: the importance of precision Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-22 Ryan Dinkele, Palwasha Y Khan, Digby F Warner
-
-
A step forward in the journey towards hookworm vaccines Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-18 Jennifer Keiser, Tiffany Bouchery
-
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-18 Jeannot F Zinsou MD, Prof David J Diemert MD, Jean Claude Dejon-Agobé MD, Bayodé R Adégbité PhD, Yabo Josiane Honkpehedji MD, Kafui G Vodonou MSc, Rodrigue Bikangui MSc, Jean Ronald Edoa MD, Marguerite Massinga Loembe PhD, Guangzhao Li MS, Prof Maria Yazdanbakhsh PhD, Prof Maria Elena Bottazzi PhD, Remko van Leeuwen MD, Prof Peter G Kremsner MD, Prof Peter J Hotez PhD, Prof Jeffrey M Bethony PhD, Prof
A human hookworm vaccine is being developed to protect children against iron deficiency and anaemia associated with chronic infection with hookworms. aspartic protease-1 (-APR-1) and glutathione S-transferase-1 (-GST-1) are components of the blood digestion pathway critical to hookworm survival in the host. Recombinant -GST-1 and catalytically inactive -APR-1 (-APR-1[M74]) adsorbed to Alhydrogel were
-
The hidden threat of subclinical tuberculosis Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-12 Xiaolin Wei, Wenhong Zhang
-
Prevalence of subclinical pulmonary tuberculosis in adults in community settings: an individual participant data meta-analysis Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-12 Logan Stuck PhD, Eveline Klinkenberg PhD, Nahid Abdelgadir Ali MD, Egbal Ahmed Basheir Abukaraig MD, Yaw Adusi-Poku MD, Zeleke Alebachew Wagaw MD, Razia Fatima MD, Nathan Kapata PhD, Pascalina Kapata-Chanda PhD, Bruce Kirenga PhD, Llang B Maama-Maime MD, Prof Sayoki G Mfinanga PhD, Sizulu Moyo PhD, Lindiwe Mvusi MD, Ndahafa Nandjebo RN, Hai Viet Nguyen PhD, Hoa Binh Nguyen PhD, Joshua Obasanya MD,
Subclinical pulmonary tuberculosis, which presents without recognisable symptoms, is frequently detected in community screening. However, the disease category is poorly clinically defined. We explored the prevalence of subclinical pulmonary tuberculosis according to different case definitions. We did a one-stage individual participant data meta-analysis of nationally representative surveys that were
-
Accelerating antibiotic access and stewardship: a new model to safeguard public health Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-11 Jennifer Cohn MD, Prof Marc Mendelson PhD, Prof Souha S Kanj MD, Nusrat Shafiq DM, Icaro Boszczowski MD, Ramanan Laxminarayan PhD
This Personal View discusses the challenges faced, especially by low-income and middle-income countries (LMICs), in responding to the growing burden of bacterial antimicrobial resistance. Many patients in LMICs lack access to effective and affordable treatments needed to successfully treat patients. Meanwhile, traditional antimicrobial stewardship models face implementation challenges due to financial
-
Consensus definitions in imported human schistosomiasis: a GeoSentinel and TropNet Delphi study Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-08 Francesca Tamarozzi PhD, Cristina Mazzi MSc, Prof Spinello Antinori MD, Marta Arsuaga PhD, Prof Sören L Becker PhD, Prof Emmanuel Bottieau PhD, Daniel Camprubi-Ferrer PhD, Prof Eric Caumes PhD, Alexandre Duvignaud MD, Prof Martin P Grobusch FRCP, Prof Stephane Jaureguiberry PhD, Sabine Jordan MD, Andreas Mueller MD, Andreas Neumayr MD, Jose A Perez-Molina PhD, Joaquin Salas-Coronas PhD, Fernando Salvador
Terminology in schistosomiasis is not harmonised, generating misunderstanding in data interpretation and clinical descriptions. This study aimed to achieve consensus on definitions of clinical aspects of schistosomiasis in migrants and returning travellers. We applied the Delphi method. Experts from institutions affiliated with GeoSentinel and TropNet, identified through clinical and scientific criteria
-
Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-06 Ruiqi Zhang, Ivan Fan-Ngai Hung
-
Untold Lassa fever story: a physician's lived experience Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-06 Q, u, d, u, s, , O, l, a, j, i, d, e, , L, a, w, a, l
-
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-06 Chijioke Bennett MD, Wayne Woo MS, Mark Bloch MBBS, King Cheung MD, Paul Griffin MBBS, Rahul Mohan MD, Sachin Deshmukh MBBS, Mark Arya MD, Oscar Cumming BMed, A Munro Neville MBBS, Toni G McCallum Pardey MS, Joyce S Plested PhD, Shane Cloney-Clark BS, Mingzhu Zhu PhD, Raj Kalkeri PhD, Nita Patel MS, Alex Marcheschi PharmD, Jennifer Swan BS, Gale Smith PhD, Iksung Cho MS, Gregory M Glenn MD, Robert
SARS-CoV-2 variants evade immunity despite vaccination with prototype COVID-19 vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating immune responses after two booster doses of a vaccine containing the omicron BA.5 subvariant spike protein in adults previously vaccinated with a prototype mRNA vaccine. This interim analysis reports on day 28 immunogenicity and safety outcomes
-
A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-05 Manu P Bilsen MD, Prof Simon P Conroy PhD, Caroline Schneeberger MD, Tamara N Platteel MD, Cees van Nieuwkoop MD, Prof Lona Mody MD, Prof Jeffrey M Caterino MD, Prof Suzanne E Geerlings MD, Bela Köves MD, Prof Florian Wagenlehner MD, Marleen Kunneman PhD, Prof Leo G Visser MD, Merel M C Lambregts MD, UTI Reference Standard Consensus Group, Thomas Hooton, Lindsay Nicolle, Barbara Trautner, Kalpana Gupta
The absence of a consensus-based reference standard for urinary tract infection (UTI) research adversely affects the internal and external validity of diagnostic and therapeutic studies. This omission hinders the accumulation of evidence for a disease that imposes a substantial burden on patients and society, particularly in an era of increasing antimicrobial resistance. We did a three-round Delphi
-
Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-04 Dan-Yu Lin, Shuaiqi Huang, Alex Milinovich, Abhijit Duggal, Xiaofeng Wang
-
Progress towards safer and more effective radical cure of Plasmodium vivax Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-04 R, i, c, , N, , P, r, i, c, e
-
Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-04 Katharina Kocher, Carolin Moosmann, Felix Drost, Christine Schülein, Pascal Irrgang, Philipp Steininger, Jahn Zhong, Johannes Träger, Bernd Spriewald, Christoph Bock, Dirk H Busch, Christian Bogdan, Benjamin Schubert, Thomas H Winkler, Matthias Tenbusch, Ev-Marie Schuster, Kilian Schober
-
Is eradication of influenza B viruses possible? Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-04 Marios Koutsakos, Steven Rockman, Florian Krammer
-
Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study Lancet Infect Dis (IF 56.3) Pub Date : 2024-03-04 Marcelo Brito PhD, Rosilene Rufatto BSc, José Diego Brito-Sousa PhD, Felipe Murta PhD, Vanderson Sampaio PhD, Patrícia Balieiro MSc, Djane Baía-Silva PhD, Vanessa Castro BSc, Brenda Alves BSc, Aline Alencar MD, Stephan Duparc MD, Penny Grewal Daumerie MBA, Isabelle Borghini-Fuhrer PhD, Elodie Jambert PharmD, Cássio Peterka MSc, Francisco Edilson Lima Jr MSc, Leonardo Carvalho Maia BSc, Catherine Lucena
Prevention of malaria recurrence is essential for malaria elimination in Brazil. We evaluated the real-world effectiveness of an updated treatment algorithm for radical cure in the Brazilian Amazon. In this non-interventional observational study, we used retrospective data from the implementation of a treatment algorithm at 43 health facilities in Manaus and Porto Velho, Brazil. The treatment algorithm
-
Malaria vaccine development in Mali: a step towards transmission-blocking strategies Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-23 Amira Mohamed Taha, Dang Nguyen, Juan J Montenegro-Idrogo, Alfonso J Rodriguez-Morales
-
Surge of cutaneous leishmaniasis in Pakistan Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-22 Sharmila Devi
-
-
-
West Nile meningoencephalitis in infants: look for thalamic involvement Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Léa Rossillon, Aurélie Hayotte, Marion Caseris, Gilda Grard, Alexandra Ntorkou, Michael Levy
-
The rise of syphilis: a call to action for dermatologists Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Hitaishi Mehta, Anuradha Bishnoi, Keshavamurthy Vinay
-
Climate change recognised in World malaria report 2023 Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Sanjeet Bagcchi
-
UNICEF report reveals gender gaps persist in HIV Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Manjulika Das
-
Risk of dengue spread is high globally, says WHO Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Talha Burki
-
Operational addendum for One Health Joint Plan of Action Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Timothy Jesudason
-
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution: a secondary analysis of a cluster-randomised controlled trial in Benin Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Manfred Accrombessi, Jackie Cook, Edouard Dangbenon, Arthur Sovi, Boulais Yovogan, Landry Assongba, Constantin J Adoha, Bruno Akinro, Cyriaque Affoukou, Germain Gil Padonou, Immo Kleinschmidt, Louisa A Messenger, Mark Rowland, Corine Ngufor, Martin C Akogbeto, Natacha Protopopoff
-
Infectious disease surveillance update Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Ruth Zwizwai
-
Aleksandra Barac—a global focus on fungal infections Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Tony Kirby
-
Peer review at The Lancet Infectious Diseases in 2023 Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Ursula Hofer
-
Is the next generation of mosquito nets surviving expectations? Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Sarah Moore, Stephan Karl
-
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2023 Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21
-
-
-
The next chapter for Africa's genomic initiatives Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-21 Paul Adepoju
-
Global incidence and mortality of severe fungal disease Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-20 Kevin S Ikuta, Tomislav Meštrović, Mohsen Naghavi
-
Global incidence and mortality of severe fungal disease – Author's reply Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-20 David W Denning
-
Guinea worm disease inched closer to eradication in 2023 Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-19 Alix Boisson-Walsh
-
Access to respiratory syncytial virus preventive tools for neonates and infants in Europe Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-19 Caitlin Pley, Beate Kampmann
-
The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-16 Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach
-
Transjugular intrahepatic portosystemic shunt followed by splenectomy for complicated hepatosplenic schistosomiasis: a case report and review of the literature Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-15 Francesca Tamarozzi, Tamara Ursini, Giacomo Stroffolini, Geraldo Badona Monteiro, Dora Buonfrate, Veronica Andrea Fittipaldo, Simone Conci, Clizia Gasparini, Giancarlo Mansueto, Alfredo Guglielmi, Federico Gobbi
-
-
-
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-15 Inès Fafi, Zein Assad, Léa Lenglart, Zaba Valtuille, Naïm Ouldali
-
-
Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-14 Lao-Tzu Allan-Blitz, Helen Fifer, Jeffrey D Klausner
-
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-12 Xiaojiao Li, Yusi Liu, Meng Wang, Lei Gao, Jingrui Liu, Hong Zhang, Min Wu, Hong Chen, Jinfeng Lou, Jing Wang, Jing Chen, Guozhu Geng, Zhenkun Ma, Yanhua Ding
-
ChatGPT does not neglect a neglected disease, if appropriately prompted – Authors' reply Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-12 Mathieu Nacher, Ugo Françoise, Antoine Adenis
-
A novel dual targeted antibacterial agent for Helicobacter pylori Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-12 Jinnan Chen, Hong Lu
-
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-09 Nora Schmit, Hillary M Topazian, H Magloire Natama, Duncan Bellamy, Ousmane Traoré, M Athanase Somé, Toussaint Rouamba, Marc Christian Tahita, Massa dit Achille Bonko, Aboubakary Sourabié, Hermann Sorgho, Lisa Stockdale, Samuel Provstgaard-Morys, Jeremy Aboagye, Danielle Woods, Katerina Rapi, Mehreen S Datoo, Fernando Ramos Lopez, Giovanni D Charles, Kelly McCain, Jean-Bosco Ouedraogo, Mainga Hamaluba
-
Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-09 Hyolim Kang, Megan Auzenbergs, Hannah Clapham, Clara Maure, Jong-Hoon Kim, Henrik Salje, Christopher G Taylor, Ahyoung Lim, Andrew Clark, W John Edmunds, Sushant Sahastrabuddhe, Oliver J Brady, Kaja Abbas
-
Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-09 Christina C Chang, Thomas S Harrison, Tihana A Bicanic, Methee Chayakulkeeree, Tania C Sorrell, Adilia Warris, Ferry Hagen, Andrej Spec, Rita Oladele, Nelesh P Govender, Sharon C Chen, Christopher H Mody, Andreas H Groll, Yee-Chun Chen, Michail S Lionakis, Alexandre Alanio, Elizabeth Castañeda, Jairo Lizarazo, José E Vidal, Takahiro Takazono, Martin Hoenigl, Jan-Willem Alffenaar, Jean-Pierre Gangneux
-
Pharmacological innovation and clinical value of VV116 Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-07 Mengxi Jiang, Yuan Gao, Zhongjie Hu
-
Persistent SARS-CoV-2 infection: significance and implications Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-07 Heather M Machkovech, Anne M Hahn, Jacqueline Garonzik Wang, Nathan D Grubaugh, Peter J Halfmann, Marc C Johnson, Jacob E Lemieux, David H O'Connor, Anne Piantadosi, Wanting Wei, Thomas C Friedrich
-
Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-07 Rebecca M Coulborn, Mathieu Bastard, Nicolas Peyraud, Etienne Gignoux, Francisco Luquero, Bérengère Guai, Stephane Hans Bateyi Mustafa, Elisabeth Mukamba Musenga, Steve Ahuka-Mundeke
-
Combining vaccines, optimised supportive care, and therapeutics for Ebola virus disease increases survival Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-07 William A Fischer, David A Wohl
-
Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort study Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-06 Reena H Doshi, Patrick K Mukadi, Rebecca M Casey, Gabriel M Kizito, Hongjiang Gao, Beatrice Nguete U, Janeen Laven, Lilliane Sabi, Didine K Kaba, Jean-Jacques Muyembe-Tamfum, Terri B Hyde, Steve Ahuka-Mundeke, J Erin Staples
-
Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-06 Aitana Juan-Giner, George Warimwe
-
Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial Lancet Infect Dis (IF 56.3) Pub Date : 2024-02-05 Zifeng Yang, Zhengtu Li, Yangqing Zhan, Zhengshi Lin, Zhonghao Fang, Xiaowei Xu, Lin Lin, Haijun Li, Zejun Lin, Changyuan Kang, Jingyi Liang, Shiwei Liang, Yongming Li, Shaoqiang Li, Xinyun Yang, Feng Ye, Nanshan Zhong, Ping Zhang, Xiaoguang Li, Jie Peng, Sanjing Li, Rongmeng Jiang, Xiaolin Chen, Yingyun Fu, Huiqing Zeng, Xiaoju Zhang, Wei Zhang, Shenghui Yu, Feng Gao, Changqing Lin, Deguang Mu, Yanfen
Background Onradivir (ZSP1273) is a novel anti-influenza A virus inhibitor. Preclinical studies show that onradivir can inhibit influenza A H1N1 and H3N2 replication and increase the survival rate of infected animals. In this study, we aimed to evaluate the safety and efficacy of three onradivir dosing regimens versus placebo in outpatients with acute uncomplicated influenza A virus infection. Methods